A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant (NCT05675930)
A Multi-Center, Phase II, Randomized Double-Blind Trial to Evaluate the Efficacy and Safety of Photobiomodulation for the Treatment of Oral Chronic Graft-Versus-Host Disease After Allogeneic Stem Cell Transplantation (the LIGHT Trial)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to find out whether photobiomodulation/PBM therapy using the Thor LX2.3 therapy system is a safe and effective treatment for oral Graft-Versus-Host Disease/GVHD.
Who can join: Review the eligibility criteria below.
Location: National Institute of Health (Data Collection AND Specimen Analysis) — Bethesda, Maryland
Age range: 4 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- National Institute of Health (Data Collection AND Specimen Analysis) — Bethesda, Maryland
- Memorial Sloan Kettering at Basking Ridge (Consent only) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Consent only) — Middletown, New Jersey
- Memorial Sloan Kettering Cancer Center @ Bergen (Consent only) — Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center @ Commack (Consent only) — Commack, New York
- Memorial Sloan Kettering Westchester (Consent only) — Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
- Memorial Sloan Kettering Cancer Center @ Nassau (Consent only) — Uniondale, New York
- University of Pittsburgh Medical Center (Data Collection Only) — Pittsburgh, Pennsylvania
📞 Contact the Study Coordinator
Phone: (646) 608-2342
Email: markovaa@mskcc.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Graft-Versus-Host Disease
- De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis — Milwaukee, Wisconsin
- Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives — Bethesda, Maryland
- Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD) — New Hyde Park, New York
Explore by condition: All Graft-Versus-Host Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.